Condyloma – Pipeline Review, 2019

Condyloma is a type of sexually transmitted disease resulting in wart-like growth in the area around the anus, glans penis, or vulva. Condyloma can be divided into three types, namely condyloma acuminatum (genital warts), condyloma latum and condyloma subcutaneum. Condyloma acuminatum or genital warts are most common among the three types and are caused by Human Papilloma Virus (HPV). The symptoms of Condyloma are increased vaginal discharge, grey spots in the genital area, Itching and discomfort in the genital area, grey or white lesions, and others.

Treatment for condyloma depends on the type of diseases. Medication for genital warts includes imiquimod, podophyllin, podofilox, trichloroacetic acid, sinecatechins, and others. Surgical methods for the treatment of genital warts are cryotherapy, surgical excision, electrocautery, and laser treatments.

Government initiatives for awareness regarding sexually transmitted diseases and preventive care have boosted the demand for condyloma drugs. Many clinical studies and research have been initiated for the development of new drugs for condyloma by pharmaceutical companies and research institutes. For instance; V501, which is being studied by Merck & Co., Inc., is currently in phase 3 clinical trials for the treatment of condyloma acuminata.

At present, around 42% of the pipeline candidates for Condyloma are in phase3 clinical stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Condyloma – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Condyloma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Condyloma.

The report on ‘Condyloma – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Condyloma


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Condyloma


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary